Symbols / AZTR $0.25 +0.52% Azitra, Inc.

Healthcare • Biotechnology • United States • ASE
AZTR Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Francisco D. Salva
Exch · Country ASE · United States
Market Cap 4.05M
Enterprise Value 2.40M
Income -10.96M
Sales —
FCF (ttm) -6.95M
Book/sh 0.35
Cash/sh 0.13
Employees 13
Insider 10d —
IPO Jun 16, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.48
PEG —
P/S —
P/B 0.71
P/C —
EV/EBITDA -0.22
EV/Sales —
Quick Ratio 2.07
Current Ratio 2.83
Debt/Eq 11.10
LT Debt/Eq —
EPS (ttm) -2.25
EPS next Y -0.52
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-27
Earnings (prior) 2026-02-27
ROA -110.69%
ROE -230.65%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 16.19M
Shs Float 16.18M
Insider Own 3.38%
Instit Own 1.39%
Short Float 3.44%
Short Ratio 0.02
Short Interest 557.16K
52W High 2.40
vs 52W High -89.58%
52W Low 0.10
vs 52W Low 150.00%
Beta -2.17
Impl. Vol. —
Rel Volume 0.05
Avg Volume 12.45M
Volume 652.96K
Target (mean) $1.35
Tgt Median $1.35
Tgt Low $1.00
Tgt High $1.70
# Analysts 2
Recom None
Prev Close $0.25
Price $0.25
Change 0.52%
About

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.35
Mean price target
2. Current target
$0.25
Latest analyst target
3. DCF / Fair value
$-7.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.25
Low
$1.00
High
$1.70
Mean
$1.35

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-24 main Maxim Group Buy → Buy $4
News
RSS: Latest AZTR news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.01
-98.91%
0.69
+141.55%
0.28
Operating Revenue
0.00
-100.00%
0.01
-98.91%
0.69
+141.55%
0.28
Operating Expense
10.97
-0.24%
10.99
+35.10%
8.14
-16.44%
9.74
Research And Development
4.84
+2.38%
4.72
+29.65%
3.64
-40.25%
6.10
Selling General And Administration
6.13
-2.21%
6.27
+39.52%
4.49
+23.45%
3.64
General And Administrative Expense
6.13
-2.21%
6.27
+39.52%
4.49
+23.45%
3.64
Other Gand A
6.13
-2.21%
6.27
+39.52%
4.49
+23.45%
3.64
Total Expenses
10.97
-0.24%
10.99
+35.10%
8.14
-16.44%
9.74
Operating Income
-10.97
+0.17%
-10.99
-47.44%
-7.45
+21.19%
-9.45
Total Operating Income As Reported
-10.97
+0.17%
-10.99
-47.44%
-7.45
+21.19%
-9.45
EBITDA
-10.49
-23.40%
-8.50
+20.38%
-10.67
-6.49%
-10.02
Normalized EBITDA
-10.49
+16.32%
-12.53
-17.03%
-10.71
-6.84%
-10.02
Reconciled Depreciation
0.45
+1.09%
0.45
+5.33%
0.43
+4.82%
0.41
EBIT
-10.94
-22.28%
-8.95
+19.39%
-11.10
-6.43%
-10.43
Total Unusual Items
0.00
-99.99%
4.03
+11449.02%
0.03
0.00
Total Unusual Items Excluding Goodwill
0.00
-99.99%
4.03
+11449.02%
0.03
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-10.96
-22.17%
-8.97
+20.53%
-11.28
-5.65%
-10.68
Pretax Income
-10.95
-22.20%
-8.96
+20.49%
-11.27
-5.49%
-10.68
Net Non Operating Interest Income Expense
0.06
-43.27%
0.11
+166.44%
-0.17
+32.75%
-0.25
Interest Expense Non Operating
0.01
-37.61%
0.01
-92.75%
0.17
-33.41%
0.25
Net Interest Income
0.06
-43.27%
0.11
+166.44%
-0.17
+32.75%
-0.25
Interest Expense
0.01
-37.61%
0.01
-92.75%
0.17
-33.41%
0.25
Interest Income Non Operating
0.07
-42.71%
0.12
+7671.27%
0.00
-67.27%
0.00
Interest Income
0.07
-42.71%
0.12
+7671.27%
0.00
-67.27%
0.00
Other Income Expense
-0.04
-102.24%
1.92
+152.50%
-3.65
-272.54%
-0.98
Other Non Operating Income Expenses
-0.04
+97.95%
-2.12
+42.52%
-3.68
-276.11%
-0.98
Gain On Sale Of Security
0.00
-99.99%
4.03
+11449.02%
0.03
—
Tax Provision
0.01
-7.88%
0.01
-47.82%
0.02
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
-99.99%
0.85
+11449.02%
0.01
0.00
Net Income Including Noncontrolling Interests
-10.96
-22.17%
-8.97
+20.53%
-11.28
-5.65%
-10.68
Net Income From Continuing Operation Net Minority Interest
-10.96
-22.17%
-8.97
+20.53%
-11.28
-5.65%
-10.68
Net Income From Continuing And Discontinued Operation
-10.96
-22.17%
-8.97
+20.53%
-11.28
-5.65%
-10.68
Net Income Continuous Operations
-10.96
-22.17%
-8.97
+20.53%
-11.28
-5.65%
-10.68
Normalized Income
-10.96
+9.86%
-12.15
-7.45%
-11.31
-5.91%
-10.68
Net Income Common Stockholders
-10.96
-22.17%
-8.97
+29.05%
-12.64
+6.02%
-13.45
Diluted EPS
—
-15.70
+95.71%
-366.17
-64.70%
-222.33
Basic EPS
—
-15.70
+95.71%
-366.17
-64.70%
-222.33
Basic Average Shares
—
0.57
+1554.87%
0.03
-42.95%
0.06
Diluted Average Shares
—
0.57
+1554.87%
0.03
-42.95%
0.06
Diluted NI Availto Com Stockholders
-10.96
-22.17%
-8.97
+29.05%
-12.64
+6.02%
-13.45
Preferred Stock Dividends
—
—
1.36
-51.05%
2.77
Line Item Trend 2023-12-31
Total Assets
5.12
Current Assets
2.54
Cash Cash Equivalents And Short Term Investments
1.80
Cash And Cash Equivalents
1.80
Receivables
0.22
Accounts Receivable
0.10
Taxes Receivable
0.13
Prepaid Assets
0.45
Current Deferred Assets
0.07
Total Non Current Assets
2.58
Net PPE
1.58
Gross PPE
1.98
Accumulated Depreciation
-0.40
Properties
0.00
Buildings And Improvements
0.01
Machinery Furniture Equipment
0.06
Other Properties
1.88
Leases
0.03
Goodwill And Other Intangible Assets
0.21
Other Intangible Assets
0.21
Non Current Deferred Assets
0.74
Other Non Current Assets
0.05
Total Liabilities Net Minority Interest
2.20
Current Liabilities
1.60
Payables And Accrued Expenses
1.25
Payables
0.90
Accounts Payable
0.90
Current Accrued Expenses
0.35
Pensionand Other Post Retirement Benefit Plans Current
0.03
Total Tax Payable
0.00
Income Tax Payable
0.00
Current Debt And Capital Lease Obligation
0.32
Current Capital Lease Obligation
0.32
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
0.60
Long Term Debt And Capital Lease Obligation
0.56
Long Term Debt
—
Long Term Capital Lease Obligation
0.56
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
2.91
Common Stock Equity
2.91
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.06
Ordinary Shares Number
0.06
Treasury Shares Number
0.00
Additional Paid In Capital
51.51
Retained Earnings
-48.60
Total Equity Gross Minority Interest
2.91
Total Capitalization
2.91
Working Capital
0.93
Invested Capital
2.91
Total Debt
0.89
Net Debt
—
Capital Lease Obligations
0.89
Net Tangible Assets
2.70
Tangible Book Value
2.70
Derivative Product Liabilities
0.04
Interest Payable
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-11.22
-10.22%
-10.18
-38.32%
-7.36
+11.82%
-8.35
Cash Flow From Continuing Operating Activities
-11.22
-10.22%
-10.18
-38.32%
-7.36
+11.82%
-8.35
Net Income From Continuing Operations
-10.96
-22.17%
-8.97
+20.53%
-11.28
-5.65%
-10.68
Depreciation Amortization Depletion
0.45
+1.09%
0.45
+5.33%
0.43
+4.82%
0.41
Depreciation
0.44
+0.54%
0.44
+4.59%
0.42
+2.94%
0.41
Amortization Cash Flow
0.01
+22.83%
0.01
+46.06%
0.01
—
Depreciation And Amortization
0.45
+1.09%
0.45
+5.33%
0.43
+4.82%
0.41
Amortization Of Intangibles
0.01
+22.83%
0.01
+46.06%
0.01
—
Other Non Cash Items
0.01
-99.49%
2.13
-43.82%
3.80
+166.85%
1.42
Stock Based Compensation
0.06
-74.40%
0.25
+61.75%
0.15
-17.87%
0.18
Asset Impairment Charge
0.00
-100.00%
0.44
+26.02%
0.35
0.00
Operating Gains Losses
0.00
+100.04%
-4.04
-8035.96%
-0.05
-799.77%
0.01
Gain Loss On Investment Securities
-0.00
+99.99%
-4.03
-11482.18%
-0.03
-4142.39%
-0.00
Net Foreign Currency Exchange Gain Loss
0.00
+100.00%
-0.01
0.00
—
Gain Loss On Sale Of PPE
0.00
-57.42%
0.00
-88.27%
0.04
+422.74%
0.01
Change In Working Capital
-0.80
-80.48%
-0.44
+41.37%
-0.75
-342.45%
0.31
Change In Receivables
-0.04
-134.34%
0.11
+168.50%
0.04
-35.90%
0.07
Changes In Account Receivables
-0.00
-100.69%
0.10
+15.91%
0.08
+485.21%
-0.02
Change In Prepaid Assets
0.05
+144.57%
-0.12
+58.59%
-0.29
-478.05%
-0.05
Change In Payables And Accrued Expense
-0.50
-256.01%
-0.14
-104.61%
-0.07
-116.32%
0.42
Change In Payable
—
-0.14
-104.61%
-0.07
-116.32%
0.42
Change In Account Payable
—
-0.14
-104.61%
-0.07
-116.32%
0.42
Change In Other Working Capital
-0.01
-128.88%
0.02
+111.80%
-0.16
-210.64%
0.14
Change In Other Current Assets
-0.00
-156.29%
0.00
+423.72%
-0.00
-136.46%
0.00
Change In Other Current Liabilities
-0.30
+3.46%
-0.32
-11.56%
-0.28
-5.43%
-0.27
Investing Cash Flow
-0.18
+51.77%
-0.38
-19.16%
-0.32
+5.49%
-0.34
Cash Flow From Continuing Investing Activities
-0.18
+51.77%
-0.38
-19.16%
-0.32
+5.49%
-0.34
Net PPE Purchase And Sale
-0.02
-145.77%
-0.01
+67.72%
-0.03
+8.00%
-0.03
Purchase Of PPE
-0.02
-182.57%
-0.01
+67.72%
-0.03
+19.81%
-0.03
Sale Of PPE
0.00
0.00
0.00
-100.00%
0.00
Capital Expenditure
-0.19
+50.94%
-0.38
-19.16%
-0.32
+6.67%
-0.34
Capital Expenditure Reported
-0.16
+56.34%
-0.37
-27.07%
-0.29
+5.26%
-0.31
Net Intangibles Purchase And Sale
—
—
—
-0.13
Purchase Of Intangibles
—
—
—
-0.13
Net Other Investing Changes
—
—
—
-0.18
Financing Cash Flow
8.92
-33.04%
13.32
+122.62%
5.98
+44.73%
4.13
Cash Flow From Continuing Financing Activities
8.92
-33.04%
13.32
+122.62%
5.98
+44.73%
4.13
Net Issuance Payments Of Debt
-0.02
-10.02%
-0.01
-97.48%
-0.01
-100.17%
4.35
Issuance Of Debt
—
—
0.00
-100.00%
4.35
Repayment Of Debt
-0.02
-10.02%
-0.01
-97.48%
-0.01
0.00
Long Term Debt Issuance
—
—
0.00
-100.00%
4.35
Long Term Debt Payments
-0.02
-10.02%
-0.01
-97.48%
-0.01
0.00
Net Long Term Debt Issuance
-0.02
-10.02%
-0.01
-97.48%
-0.01
-100.17%
4.35
Net Common Stock Issuance
9.03
-32.36%
13.35
+122.90%
5.99
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.02
0.00
-100.00%
0.00
Net Other Financing Charges
-0.10
-158.46%
-0.04
—
-0.22
Changes In Cash
-2.49
-190.14%
2.76
+262.60%
-1.70
+62.72%
-4.55
Beginning Cash Position
4.55
+153.61%
1.80
-48.58%
3.49
-56.58%
8.04
End Cash Position
2.07
-54.59%
4.55
+153.61%
1.80
-48.58%
3.49
Free Cash Flow
-11.41
-8.02%
-10.56
-37.53%
-7.68
+11.62%
-8.69
Change In Income Tax Payable
—
—
—
0.00
Change In Tax Payable
—
—
—
0.00
Common Stock Issuance
9.03
-32.36%
13.35
+122.90%
5.99
0.00
Issuance Of Capital Stock
9.03
-32.36%
13.35
+122.90%
5.99
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category